Price
No data yet.
Social Signal Score
Analyst Ratings
35 analystsRevenue
$3.73B+54.52%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Adam H. Schechter
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 71,000
- Beta
- 0.85
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 3.33
Financials
Revenue
$3.73B+54.5%Net Income
$298.70M+66.4%EBITDA
$620.90M+28.3%Free Cash Flow
$313.90M+70.9%EPS (diluted)
$3.64+112.9%Shares Outstanding (diluted)
82.00M-21.8%Operating Expenses
$577.20MCash & Debt
$141.80MReturn of Capital
$412.50MRevenue by Segment (annual)
$10.88BDividend per Share
$0.72Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $13.95B | $876.50M | $10.54 |
| 2024 | $13.01B | $746.00M | $8.89 |
| 2023 | $12.16B | $418.00M | $4.80 |
| 2022 | $11.86B | $1.28B | $14.04 |
| 2021 | $13.14B | $2.38B | $24.58 |
| 2020 | $13.98B | $1.56B | $15.99 |
| 2019 | $11.55B | $823.80M | $8.41 |
| 2018 | $11.33B | $883.70M | $8.71 |
| 2017 | $10.44B | $1.27B | $12.39 |
| 2016 | $9.64B | $732.10M | $7.14 |
| 2015 | $8.68B | $436.90M | $4.42 |
| 2014 | $6.01B | $511.20M | $6.03 |
| 2013 | $5.81B | $573.80M | $6.70 |
| 2012 | $5.67B | $583.10M | $6.24 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from LH's reported EPS growth of 4.1% a year over 13 years.
- EPS in 5 years
- $12.88
- Implied price
- $309.10
- Return from $308.49
- 0.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $153.68 — -50.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 20 | 24 | 28 | 32 |
|---|---|---|---|---|---|
| -5.9% | -16.6% | -12.8% | -9.6% | -6.7% | -4.2% |
| -0.9% | -12.2% | -8.2% | -4.8% | -1.8% | 0.9% |
| 4.1% | -7.8% | -3.5% | 0.0% | 3.2% | 6.0% |
| 9.1% | -3.3% | 1.1% | 4.8% | 8.1% | 11.1% |
| 14.1% | 1.1% | 5.7% | 9.6% | 13.1% | 16.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-66.10%Social Signal Score
Mentions (20)
- Newsprnewswire.com·6d ago·Neutral
Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026 BURLINGTON, N.C., Sept. 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc.
View source ↗ - Newszacks.com·7d ago·Neutral
Is This the Right Time to Add Labcorp Stock to Your Portfolio? LH expands specialty testing and consumer services through acquisitions, partnerships and AI, while reimbursement and cost risks remain.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Labcorp's Future Driven By Clinical Testing Demand, Despite Impact From Medicare Cuts Labcorp Holdings Inc. is upgraded to Buy, supported by resilient demand for diagnostics and robust Q2 results, despite upcoming Medicare rate cuts. LH outperformed both the S&P 500 and healthcare peers YTD, with strong technical support and positive operating margins. Revenue durability, new test launches, and a diversified biopharma segment bolster LH's growth and risk profile amid regulatory headwinds.
View source ↗ - News (RSS)investing·14d ago·Neutral
Why is Labcorp stock sliding today?
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Labcorp Holdings Inc. (LH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Labcorp Holdings Inc. (LH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·23d ago·Neutral
Labcorp Holdings Inc. (LH) Analyst/Investor Day - Slideshow
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Labcorp Holdings Inc. (LH) Analyst/Investor Day Transcript Labcorp Holdings Inc. (LH) Analyst/Investor Day Transcript
View source ↗ - Newsbenzinga.com·25d ago·Positive
Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029 Labcorp Holdings (NYSE:LH) on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day.
View source ↗ - Newsprnewswire.com·26d ago·Neutral
…ramework driven by sustainable growth, strong cash flow generation and disciplined capital deployment BURLINGTON, N.C., Sept. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today will host its 2026 Investor Day at 9 a.m.
View source ↗ - Newszacks.com·33d ago·Positive
Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - News (RSS)zerohedge·39d ago·Negative
…ent that "for millions of families navigating the uncertainty of Alzheimer's disease, a timely diagnosis is the first and most critical step toward meaningful care." Labcorp and Quest Diagnostics said they will carry the new test. Once ordered by a doctor, patients can have their blood drawn for the test in a doctor's office, a Labcorp service center, or a Quest center. Tyler Durden Thu, 08/27/2026 - 23:00
View source ↗ - Newszacks.com·41d ago·Positive
Should You Continue to Hold Labcorp Stock in Your Portfolio? LH's specialty-testing expansion, strategic partnerships and buybacks support growth, while reimbursement and cost pressures pose risks.
View source ↗ - Newsprnewswire.com·43d ago·Negative
… disease Intended for individuals 55 and older with signs, symptoms or complaints of cognitive decline BURLINGTON, N.C., Aug. 24, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA).
View source ↗ - Newsprnewswire.com·49d ago·Neutral
Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health Centers BURLINGTON, N.C. and BETHESDA, Md.
View source ↗ - News (RSS)investing·49d ago·Neutral
Labcorp stock hits all-time high at 325.75 USD
View source ↗ - Newsprnewswire.com·50d ago·Neutral
Labcorp to Host Investor Day on September 10, 2026 BURLINGTON, N.C., Aug. 17, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m.
View source ↗ - Newsfool.com·54d ago·Negative
Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million The CEO liquidated 4,669 shares at a price of $320.37 per share, totaling ~$1.5 million on August 11, 2026. The transaction resulted in a 4% reduction of the executive's total equity holdings in the company.
View source ↗ - Newszacks.com·56d ago·Positive
Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich? LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.
View source ↗ - Newszacks.com·56d ago·Positive
Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsprnewswire.com·57d ago·Negative
Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma Labcorp's FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapies Supports access to targeted treatment options for the deadliest form of skin cancer BURLINGTON, N.C., Aug. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today a
View source ↗
Earnings
Wed, Oct 28(in 3 weeks)
Consensus estimate $4.65 per share
Typical surprise +3.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$4.99 vs $4.78beat
- Thu, Apr 30$4.25 vs $4.11beat
- Tue, Feb 17$4.07 vs $3.95beat
- Tue, Oct 28$4.18 vs $4.13beat
- Thu, Jul 24$4.35 vs $4.17beat
- Tue, Apr 29$3.84 vs $3.74beat
Estimates and results for LH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LH officers and directors.
- Bought
- —
- Sold
- $10.4m
0 trades
17 trades
- Anderson Kerrii Bsold
- Schechter Adam Hsold
- Summy Amy B.sold
- Wilkinson Peter Jsold
- Wilkinson Peter Jsold
- Kyle Kathryn Wsold
- Vaughn Bryan Tsold
- Kyle Kathryn Wsold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- April Delaneyhouse · MD06 · disclosed Sep 10, 2026 (34d later)Sell$1,001 - $15,000
- April Delaneyhouse · MD06 · disclosed Sep 10, 2026 (16d later)Sell$100,001 - $250,000
- April Delaneyhouse · MD06 · disclosed Sep 10, 2026 (35d later)Sell$1,001 - $15,000
- April Delaneyhouse · MD06 · disclosed Sep 10, 2026 (36d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Tony Wiedhouse · WI08 · disclosed Mar 12, 2026 (21d later)Buy$15,001 - $50,000
- April McClain Delaneyhouse · MD06 · disclosed Mar 11, 2026 (28d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Mar 11, 2026 (35d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Feb 3, 2026 (6d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Dec 9, 2025 (22d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (18d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (18d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (18d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (18d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Nov 5, 2025 (7d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Nov 5, 2025 (5d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 10, 2025 (13d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 2, 2025 (18d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.